uniQure’s (QURE) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of uniQure (NASDAQ:QURE) in a report issued on Tuesday,Benzinga reports. The firm currently has a $24.00 price target on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the company. StockNews.com upgraded uniQure to a “sell” rating in a research note on Wednesday, December 11th. The Goldman Sachs Group boosted their price target on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Mizuho increased their price objective on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 19th. Leerink Partners boosted their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Finally, Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.38.

uniQure Stock Up 3.5 %

Shares of NASDAQ:QURE opened at $15.83 on Tuesday. The stock has a 50-day simple moving average of $12.56 and a 200-day simple moving average of $8.61. The stock has a market capitalization of $771.55 million, a P/E ratio of -3.19 and a beta of 0.41. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. Equities analysts forecast that uniQure will post -3.74 earnings per share for the current year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of QURE. FNY Investment Advisers LLC acquired a new stake in shares of uniQure during the 4th quarter valued at approximately $88,000. RTW Investments LP bought a new stake in uniQure during the third quarter valued at $49,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc bought a new position in shares of uniQure in the 3rd quarter worth about $53,000. Finally, Quarry LP acquired a new position in shares of uniQure in the 3rd quarter valued at about $58,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.